High Cholesterol (Hypercholesterolemia) and Statins (HMG‑CoA Reductase Inhibitors)

Deep Dive

From a western clinical perspective, high cholesterol drives atherosclerosis primarily through elevated concentrations of atherogenic apolipopro... From a western clinical perspective, high cholesterol drives atherosclerosis primarily through elevated concentrations of atherogenic apolipoprotein B–containing particles, notably LDL. These particles penetrate the arterial intima, become retained and modified, and trigger inflammation and plaque formation. Biomarkers map onto this biology: LDL-C tracks the atherogenic burden; non–HDL-C and apoB can refine risk; high triglycerides reflect remnant lipoproteins that also promote atherogenesis; HDL-C often inversely correlates with risk but is not a primary treatment target. Randomized trial evidence shows that the absolute reduction in LDL-C, rather than the agent used, is tightly linked to fewer cardiovascular events, with no clear threshold below which benefit ceases. Statins inhibit hepatic HMG‑CoA reductase, lowering intracellular cholesterol and upregulating LDL receptors, thereby increasing clearance of circulating LDL. Across primary and secondary prevention trials, statins reduce myocardial infarction, ischemic stroke, and cardiovascular death. Benefits are most pronounced in secondary prevention and in those with higher baseline risk, aligning with risk-based treatment algorithms. Ezetimibe, PCSK9 inhibitors, and, for certain patients, bempedoic acid, extend LDL lowering when statins alone are insufficient or not tolerated. For patients with elevated triglycerides on statins, icosapent ethyl can further reduce events, likely by addressing remnant lipoproteins and inflammation. Safety data are extensive. Myalgias are relatively common, though true myopathy is rare; severe rhabdomyolysis is very uncommon. Transaminase elevations usually resolve without sequelae; routine liver enzyme monitoring beyond baseline is not generally required unless symptoms suggest hepatotoxicity. Statins modestly increase the risk of diabetes, particularly at higher intensities and in people with metabolic risk, but for most at-risk individuals the cardiovascular benefits outweigh this hazard. Clinicians consider drug interactions—especially with CYP3A4 inhibitors (for simvastatin, lovastatin, atorvastatin), grapefruit juice, and gemfibrozil—and tailor regimens accordingly. Baseline lipids and liver enzymes are typically assessed, with repeat lipids 4–12 weeks after initiation or dose change to confirm response and guide adjustments. Lifestyle modification remains foundational. Mediterranean and Portfolio dietary patterns, regular physical activity, weight management, and smoking cessation each contribute to risk reduction and often enhance pharmacologic effects. Shared decision-making uses global risk estimation, patient values, and tolerance history to select therapy intensity, consider nonstatin options, and plan monitoring over time, including special considerations for older adults, statin intolerance, chronic kidney disease, and pregnancy.